A study to find out how safe is it to give people with asthma a new medicine called MTPS9579A

  • Respiratory Disorder
  • Asthma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Completed

This study runs in
Country
  • United Kingdom
Study Identifier:

GA41003

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This clinical trial was done to study a new medicine (MTPS9579A) for the treatment of asthma, to find out if it was safe for people with asthma. Other information researchers wanted to know included the concentration of MTPS9579A in the body after dosing, whether MTPS9579A was effective, and if the body made antibodies when exposed to MTPS9579A. Twenty-seven people who had asthma took part in this study at six study centers in one country.

      Genentech, Inc., USA. (Part of F. Hoffmann-La Roche Ltd., Switzerland). Sponsor
      Phase 1c Phase
      GA41003 Study Identifier
      All Gender
      18 to 65 Years Age
      No Healthy Volunteers

      People with asthma requiring inhaled corticosteroids and a second controller were enrolled at six study sites in one country to evaluate the safety and tolerability of MTPS9579A, an antibody drug against tryptase. Twenty-seven participants completed the study and comprised the safety-evaluable population. This was a Phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study. Results showed MTPS9579A to be tolerable with no drug-related serious side effects or drug-related non-serious side effects. The Sponsor is no longer developing MTPS9579A for asthma. This decision had nothing to do with the safety of the medicine.

      Study Summary

      This clinical trial was done to study a new medicine (MTPS9579A) for the treatment of asthma, to find out if it was safe for people with asthma. Other information researchers wanted to know included the concentration of MTPS9579A in the body after dosing, whether MTPS9579A was effective, and if the body made antibodies when exposed to MTPS9579A. Twenty-seven people who had asthma took part in this study at six study centers in one country.

      Genentech, Inc., USA. (Part of F. Hoffmann-La Roche Ltd., Switzerland). Sponsor
      Phase 1c Phase
      GA41003 Study Identifier
      MTPS9579A Treatments
      Asthma Condition
      Official Title

      A phase 1c, multicenter, randomized, observer-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of a single dose of MTPS9579A in patients with asthma requiring inhaled corticosteroids and a second controller

      Eligibility Criteria

      All Gender
      18 to 65 Years Age
      No Healthy Volunteers

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other studies on ForPatients in related disease areas.

      Asthma

      Clinical Research Explained

      Information about what clinical studies and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now